Sepsis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Sepsis Therapeutics | DelveInsight

DelveInsight's Sepsis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Sepsis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Sepsis pipeline domain.

Key takeaways from the Sepsis Clinical Trial Landscape Report
• DelveInsight's Sepsis pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Sepsis treatment.
• Key Sepsis companies such as AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Inotrem, AstraZeneca, Novartis Pharmaceuticals, and others.
• Promising Sepsis pipeline therapies in various stages of development include Enibarcimab, M 6229, SNIPR 001, Nangibotide, and others.

Request a sample and discover the recent advances in Sepsis treatment drug at https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Sepsis?
Sepsis is a life-threatening condition caused by the body's dysregulated immune response to infection, which can lead to tissue damage, organ failure, and death. It commonly develops due to bacterial, viral, fungal, or parasitic infections and may originate from infections in the lungs, urinary tract, abdomen, or skin. Symptoms include fever, rapid heart rate, rapid breathing, confusion, low blood pressure, and severe weakness. Diagnosis involves blood tests, imaging, and assessment of organ dysfunction, while treatment typically includes antibiotics, intravenous fluids, oxygen support, and intensive care management.

Emerging Sepsis Drug Profiles

Enibarcimab: AdrenoMed AG
Enibarcimab is a monoclonal antibody targeting adrenomedullin, a peptide involved in vascular integrity and endothelial stabilization. The therapy is being investigated for the treatment of septic shock and aims to improve vascular function and reduce organ damage associated with severe Sepsis. The therapy has advanced into Phase III clinical development, representing one of the most advanced Sepsis pipeline candidates currently under evaluation.

SNIPR 001: SNIPR Biome
SNIPR 001 is an investigational bacteriophage-based therapeutic designed to selectively target multidrug-resistant bacterial infections associated with Sepsis. The therapy utilizes CRISPR-enabled precision approaches to combat bacterial pathogens while minimizing disruption to the normal microbiome. The therapy is currently being evaluated in early-stage clinical studies for severe bacterial infections and Sepsis-related complications.

Learn more about the novel and emerging Sepsis pipeline therapies at: https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Sepsis Clinical Trial Landscape
• In March 2026, Shanghai Zhongshan Hospital initiated a clinical trial to evaluate whether balanced gelatin solution is more effective and safe than balanced crystalloid solution for perioperative fluid management in adults with Sepsis undergoing emergency abdominal surgery.
• In March 2026, AstraZeneca announced a study enrolling adults diagnosed with Sepsis due to suspected or confirmed bacterial infection who also developed acute kidney injury, evaluating AZD4144 versus placebo in hospitalized patients.
• In March 2026, Novartis Pharmaceuticals announced a Phase IIb study evaluating different doses of TIN816 in hospitalized adults with Sepsis-associated acute kidney injury in intensive care settings.

Scope of the Sepsis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide, Recombinant proteins, Gene Therapy
• Key Sepsis Companies: AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Inotrem, AstraZeneca, Novartis Pharmaceuticals, and others
• Key Sepsis Pipeline Therapies: Enibarcimab, M 6229, SNIPR 001, Nangibotide, and others

Dive deep into rich insights for new drugs for Sepsis treatment, visit https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Sepsis Pipeline Report Introduction
2. Sepsis Pipeline Report Executive Summary
3. Sepsis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Sepsis Pipeline Therapeutics
6. Sepsis Pipeline: Late Stage Products (Pre-registration)
7. Sepsis Pipeline: Late Stage Products (Phase III)
8. Sepsis Pipeline: Mid Stage Products (Phase II)
9. Sepsis Pipeline: Early Stage Products (Phase I)
10. Sepsis Pipeline Therapeutics Assessment
11. Inactive Products in the Sepsis Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Sepsis Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Sepsis pipeline therapeutics, reach out at https://www.delveinsight.com/sample-request/sepsis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.